Verastem to Present at the 30th Annual ROTH Conference
February 26 2018 - 07:00AM
Business Wire
Verastem, Inc. (NASDAQ:VSTM), focused on developing drugs to
improve the survival and quality of life of cancer patients, today
announced that the Company will present at the 30th Annual ROTH
Conference on Monday, March 12, 2018 at 4:30 pm PST in Dana Point,
CA, USA.
A live webcast of the presentation will be available on the
investors section of the Company’s website at www.verastem.com. An
archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company
focused on discovering and developing drugs to improve outcomes for
patients with cancer. Verastem is currently developing duvelisib, a
dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully
met its primary endpoint in the Phase 2 study DYNAMO™ in iNHL and
the Phase 3 clinical trial DUO™ in patients with chronic
lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL). Verastem has submitted a New Drug Application
(NDA) requesting the full approval of duvelisib for the treatment
of patients with relapsed or refractory CLL/SLL, and accelerated
approval for the treatment of patients with relapsed or refractory
follicular lymphoma (FL). In addition, Verastem is developing the
FAK inhibitor defactinib, which is currently being evaluated in
three separate clinical collaborations in combination with
immunotherapeutic agents for the treatment of several different
cancer types, including pancreatic cancer, ovarian cancer,
non-small cell lung cancer, and mesothelioma. Verastem’s product
candidates seek to treat cancer by modulating the local tumor
microenvironment, enhancing anti-tumor immunity, and reducing
cancer stem cells. For more information, please visit
www.verastem.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180226005124/en/
Verastem, Inc.Marianne M. Lambertson, 781-292-4273Vice
President, Corporate CommunicationsInvestor Relations/Public
Relationsmlambertson@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Mar 2023 to Mar 2024